Research and Markets: The 2012 Clinical Chemistry and Immunodiagnostics Markets: US, Europe and Japan - Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qb5xht/the_2012_clinical) has announced the addition of the "The 2012 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan--Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers" report to their offering.

“The 2012 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan--Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers”

During the next decade, the clinical chemistry and immunodiagnostics markets will undergo significant transformation. The changes will be caused convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, will resemble commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.

"The Clinical Chemistry and Immunodiagnostics Markets" is a unique worldwide market intelligence and technology assessment study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and develop effective strategic responses. The study explores future trends in the U.S., five major European countries and Japan; provides estimates of the specimen, test and sales volumes, as well as major suppliers' sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities facing suppliers during the next ten years.

Companies Mentioned

- Abbott

- AdnaGen

- Ambrilia

- AMDL

- Beckman Coulter

- Biomedical Diagnostics

- bioMerieux

- Bio-Rad

- Canag Diagnostics

- Dako

- Diasorin